Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)
10.82
+0.82 (8.20%)
NASDAQ · Last Trade: Nov 1st, 7:41 PM EDT
Detailed Quote
Previous Close
10.00
Open
10.18
Bid
10.50
Ask
10.98
Day's Range
10.06 - 10.97
52 Week Range
6.685 - 10.97
Volume
2,468,056
Market Cap
10.82K
PE Ratio (TTM)
1,082.00
EPS (TTM)
0.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,522,410
Chart
About Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)
Amneal Pharmaceuticals is a leading pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company offers a broad portfolio of high-quality, cost-effective medications across various therapeutic areas, including central nervous system disorders, infectious diseases, and pain management. Amneal is committed to improving access to essential medications through innovation in drug formulation and delivery. With a robust pipeline of products and a dedication to regulatory compliance, Amneal aims to meet the diverse needs of patients and healthcare providers while contributing to the overall efficiency of the healthcare system. Read More
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX)
jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations and raised its full-year forecast.
Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS.
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was 22.9% above analysts’ consensus estimates.
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒
BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 The Brekiya autoinjector is now available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Kashiv BioSciences, LLC, a fully-integrated biopharmaceutical company, announced that they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA), for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab).
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX)
jumped 4.7% in the afternoon session after the company announced it received U.S. Food and Drug Administration (FDA) approval for its generic narcolepsy drug, sodium oxybate oral solution.
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. The product is eligible for 180-day exclusivity under the FDA’s Competitive Generic Therapy (CGT) designation. Product launch is planned for the fourth quarter of 2025.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
